应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
MLYS Mineralys Therapeutics, Inc.
休市中 12-05 16:00:00 EST
38.50
-0.41
-1.05%
盘后
38.50
+0.00
0.00%
17:55 EST
最高
39.72
最低
37.61
成交量
98.96万
今开
39.50
昨收
38.91
日振幅
5.42%
总市值
30.47亿
流通市值
21.46亿
总股本
7,914万
成交额
3,812万
换手率
1.78%
流通股本
5,573万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Mineralys Therapeutics第三季度每股收益为-0.52美元
投资观察 · 11-20
Mineralys Therapeutics第三季度每股收益为-0.52美元
Mineralys Therapeutics宣布于2025年美国肾脏学会肾脏周(ASN Kidney Week)上进行Lorundrostat的第二阶段Explore-Ckd试验的最新报告
美股速递 · 10-21
Mineralys Therapeutics宣布于2025年美国肾脏学会肾脏周(ASN Kidney Week)上进行Lorundrostat的第二阶段Explore-Ckd试验的最新报告
Mineralys Therapeutics完成Lorundrostat治疗阻塞性睡眠呼吸暂停和高血压的2期Explore-Osa试验招募
美股速递 · 09-30
Mineralys Therapeutics完成Lorundrostat治疗阻塞性睡眠呼吸暂停和高血压的2期Explore-Osa试验招募
Mineralys Therapeutics公布III期Launch-HTN试验亚组分析结果,证实Lorundrostat在高未满足医疗需求高血压患者中的疗效与安全性
美股速递 · 09-05
Mineralys Therapeutics公布III期Launch-HTN试验亚组分析结果,证实Lorundrostat在高未满足医疗需求高血压患者中的疗效与安全性
Mineralys完成2.5亿美元股票发行定价
环球市场播报 · 09-03
Mineralys完成2.5亿美元股票发行定价
Mineralys Therapeutics宣布扩大规模的2.5亿美元承销公开发行普通股定价
美股速递 · 09-03
Mineralys Therapeutics宣布扩大规模的2.5亿美元承销公开发行普通股定价
Mineralys Therapeutics, Inc.盘中异动 下午盘大幅下挫5.14%
市场透视 · 06-13
Mineralys Therapeutics, Inc.盘中异动 下午盘大幅下挫5.14%
Mineralys Therapeutics获杰富瑞投资银行首次覆盖,给予持有评级, 目标价15.00美元。
金融界 · 06-11
Mineralys Therapeutics获杰富瑞投资银行首次覆盖,给予持有评级, 目标价15.00美元。
美股异动 | 发布高血压药物研究的积极结果 Mineralys Therapeutics(MLYS.US)暴涨超53%
智通财经 · 03-10
美股异动 | 发布高血压药物研究的积极结果 Mineralys Therapeutics(MLYS.US)暴涨超53%
Mineralys Therapeutics, Inc.盘中异动 快速拉升34.03%
市场透视 · 03-10
Mineralys Therapeutics, Inc.盘中异动 快速拉升34.03%
Mineralys Therapeutics, Inc.盘中异动 早盘股价大涨5.19%报10.53美元
市场透视 · 03-06
Mineralys Therapeutics, Inc.盘中异动 早盘股价大涨5.19%报10.53美元
Mineralys Therapeutics, Inc.盘中异动 早盘快速拉升5.06%
市场透视 · 02-27
Mineralys Therapeutics, Inc.盘中异动 早盘快速拉升5.06%
Mineralys Therapeutics, Inc.盘中异动 早盘急速拉升5.25%
市场透视 · 02-26
Mineralys Therapeutics, Inc.盘中异动 早盘急速拉升5.25%
Mineralys Therapeutics, Inc.盘中异动 股价大跌5.27%报9.70美元
市场透视 · 02-19
Mineralys Therapeutics, Inc.盘中异动 股价大跌5.27%报9.70美元
Mineralys Therapeutics, Inc.2024财年实现净利润-1.78亿美元,同比减少147.57%
市场透视 · 02-16
Mineralys Therapeutics, Inc.2024财年实现净利润-1.78亿美元,同比减少147.57%
高盛:维持Mineralys Therapeutics(MLYS.US)评级,由买入调整至买入评级, 目标价由28.00美元调整至24.00美元。
金融界 · 02-14
高盛:维持Mineralys Therapeutics(MLYS.US)评级,由买入调整至买入评级, 目标价由28.00美元调整至24.00美元。
Mineralys Therapeutics 第四季度每股收益(0.98)美元,超出(1.04)美元预期
财报速递 · 02-12
Mineralys Therapeutics 第四季度每股收益(0.98)美元,超出(1.04)美元预期
Mineralys Therapeutics, Inc.盘中异动 早盘股价大跌5.21%
市场透视 · 02-11
Mineralys Therapeutics, Inc.盘中异动 早盘股价大跌5.21%
Mineralys Therapeutics, Inc.盘中异动 早盘股价大涨5.01%报10.55美元
市场透视 · 02-07
Mineralys Therapeutics, Inc.盘中异动 早盘股价大涨5.01%报10.55美元
Mineralys Therapeutics, Inc.盘中异动 早盘股价大涨5.39%报10.76美元
市场透视 · 02-05
Mineralys Therapeutics, Inc.盘中异动 早盘股价大涨5.39%报10.76美元
加载更多
公司概况
公司名称:
Mineralys Therapeutics, Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Mineralys Therapeutics, Inc.最初成立于2019年5月31日,是特拉华州的一家公司。该公司是一家临床阶段生物制药公司,专注于开发药物,以治疗由异常升高的醛固酮引起的疾病。该公司的候选产品氯隆前列素是一种专有的口服高选择性醛固酮合酶抑制剂(ASI),该公司最初开发用于治疗未控制的高血压(uHTN)患者,定义为尽管服用了两种或多种抗高血压药物或抵抗性高血压(rHTN),但血压仍不能达到130/80mmHg以下的个体。在美国,有超过1.15亿患者患有持续性高血压(BP)或高血压,超过一半的患者未能实现血压目标,即目前可用的药物血压为130/80 mmHg。超过3000万接受治疗的患者没有达到血压目标,其中约2000万患者的收缩压水平超过140 mmHg。尽管服用了两种或两种以上药物,但高血压患者仍持续存在,心血管疾病或中风导致的死亡率风险分别为1.8倍和2.5倍。在一项评估200名uHTN和rHTN(目标HTN)受试者的第2阶段临床试验中,洛龙前列素显示,每天给药一次,血压下降具有临床意义和统计学意义,且耐受性良好。除高血压外,该公司还打算开发用于治疗慢性肾脏病(CKD)的氯前列素。
发行价格:
--
{"stockData":{"symbol":"MLYS","market":"US","secType":"STK","nameCN":"Mineralys Therapeutics, Inc.","latestPrice":38.5,"timestamp":1764968400000,"preClose":38.91,"halted":0,"volume":989556,"hourTrading":{"tag":"盘后","latestPrice":38.5,"preClose":38.5,"latestTime":"17:55 EST","volume":26668,"amount":1026694.6,"timestamp":1764975350206},"delay":0,"floatShares":55733200,"shares":79139956,"eps":-2.863576,"marketStatus":"休市中","change":-0.41,"latestTime":"12-05 16:00:00 EST","open":39.5,"high":39.72,"low":37.61,"amount":38120814.2214,"amplitude":0.054228,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.863576,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"listingDate":1676005200000,"exchange":"NASDAQ","adjPreClose":38.91,"preHourTrading":{"tag":"盘前","latestPrice":39.2,"preClose":38.91,"latestTime":"09:25 EST","volume":747,"amount":29284.412418,"timestamp":1764944730052},"postHourTrading":{"tag":"盘后","latestPrice":38.5,"preClose":38.5,"latestTime":"17:55 EST","volume":26668,"amount":1026694.6,"timestamp":1764975350206},"volumeRatio":0.7552639182142042,"optionData":{"bulkOrders":[{"symbol":"MLYS","call":false,"expireDate":1773979200000,"strike":"40.0","timestamp":1764960310263,"price":7.5,"volume":4750,"amount":3562500,"type":"+"},{"symbol":"MLYS","call":false,"expireDate":1773979200000,"strike":"30.0","timestamp":1764960310198,"price":2.25,"volume":4750,"amount":1068750,"type":"+"}]},"impliedVol":0.7067,"impliedVolPercentile":0.416},"requestUrl":"/m/hq/s/MLYS","defaultTab":"news","newsList":[{"id":"1155962014","title":"Mineralys Therapeutics第三季度每股收益为-0.52美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1155962014","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155962014?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:20","pubTimestamp":1763572801,"startTime":"0","endTime":"0","summary":"11月10日 - Mineralys Therapeutics第三季度运营费用为4113.1万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4139"],"gpt_icon":0},{"id":"1180504868","title":"Mineralys Therapeutics宣布于2025年美国肾脏学会肾脏周(ASN Kidney Week)上进行Lorundrostat的第二阶段Explore-Ckd试验的最新报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1180504868","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180504868?lang=zh_cn&edition=full","pubTime":"2025-10-21 20:01","pubTimestamp":1761048094,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics宣布于2025年美国肾脏学会肾脏周(ASN Kidney Week)上进行Lorundrostat的第二阶段Explore-Ckd试验的最新报告","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4139"],"gpt_icon":0},{"id":"1145325811","title":"Mineralys Therapeutics完成Lorundrostat治疗阻塞性睡眠呼吸暂停和高血压的2期Explore-Osa试验招募","url":"https://stock-news.laohu8.com/highlight/detail?id=1145325811","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145325811?lang=zh_cn&edition=full","pubTime":"2025-09-30 20:02","pubTimestamp":1759233764,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics宣布已完成其药物Lorundrostat治疗阻塞性睡眠呼吸暂停和高血压的2期临床试验Explore-Osa的患者招募工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4139"],"gpt_icon":0},{"id":"1184585005","title":"Mineralys Therapeutics公布III期Launch-HTN试验亚组分析结果,证实Lorundrostat在高未满足医疗需求高血压患者中的疗效与安全性","url":"https://stock-news.laohu8.com/highlight/detail?id=1184585005","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184585005?lang=zh_cn&edition=full","pubTime":"2025-09-05 21:00","pubTimestamp":1757077218,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics公布III期Launch-HTN试验亚组分析结果,证实Lorundrostat在高未满足医疗需求高血压患者中的疗效与安全性","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4139"],"gpt_icon":0},{"id":"2564739415","title":"Mineralys完成2.5亿美元股票发行定价","url":"https://stock-news.laohu8.com/highlight/detail?id=2564739415","media":"环球市场播报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564739415?lang=zh_cn&edition=full","pubTime":"2025-09-03 22:38","pubTimestamp":1756910280,"startTime":"0","endTime":"0","summary":"美股周三早盘,生物技术公司Mineralys Therapeutics(MLYS)股价下跌2.3%,此前该公司将其规模扩大后的2.5亿美元股票发行价格定为每股25.50美元。此次发行预计于2025年9月4日完成。所筹资金将用于支持公司的增长计划。\n\n\n海量资讯、精准解读,尽在新浪财经APP\n\n责任编辑:张俊 SF065","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-09-03/doc-infpftfy7581776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","MLYS"],"gpt_icon":0},{"id":"1103133923","title":"Mineralys Therapeutics宣布扩大规模的2.5亿美元承销公开发行普通股定价","url":"https://stock-news.laohu8.com/highlight/detail?id=1103133923","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103133923?lang=zh_cn&edition=full","pubTime":"2025-09-03 09:35","pubTimestamp":1756863316,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics宣布扩大规模的2.5亿美元承销公开发行普通股定价","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS"],"gpt_icon":0},{"id":"2543450544","title":"Mineralys Therapeutics, Inc.盘中异动 下午盘大幅下挫5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2543450544","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543450544?lang=zh_cn&edition=full","pubTime":"2025-06-13 03:14","pubTimestamp":1749755683,"startTime":"0","endTime":"0","summary":"北京时间2025年06月13日03时14分,Mineralys Therapeutics, Inc.股票出现异动,股价快速跳水5.14%。Mineralys Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.72%。Mineralys Therapeutics, Inc.公司简介:Mineralys Therapeutics Inc是一家临床阶段的生物制药公司,专注于开发针对由异常升高的醛固酮引起的疾病的药物。该信息摘要如下:Mineralys Therapeutics获杰富瑞投资银行首次覆盖,给予持有评级, 目标价15.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250613031443a705deff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250613031443a705deff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4539","LENZ","BK4139","MLYS"],"gpt_icon":0},{"id":"2542581148","title":"Mineralys Therapeutics获杰富瑞投资银行首次覆盖,给予持有评级, 目标价15.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2542581148","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542581148?lang=zh_cn&edition=full","pubTime":"2025-06-11 20:01","pubTimestamp":1749643271,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics(MLYS.US)获杰富瑞投资银行首次覆盖,给予持有评级, 目标价15.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250611200510977ae81e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250611200510977ae81e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","MLYS","JEF"],"gpt_icon":0},{"id":"2518274596","title":"美股异动 | 发布高血压药物研究的积极结果 Mineralys Therapeutics(MLYS.US)暴涨超53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518274596","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518274596?lang=zh_cn&edition=full","pubTime":"2025-03-10 23:32","pubTimestamp":1741620734,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,周一,Mineralys Therapeutics(MLYS.US)逆势暴涨超53%,报16.25美元。消息面上,该公司周一报告了其Lorundrostat药物候选治疗不受控制或耐药性高血压的两项关键研究的积极初步结果。Mineralys表示其三期 Launch-HTN 和二期 Advance-HTN 研究在预先规定的主要疗效终点上达到了统计学显著性,并且具有临床意义,同时显示出良好的安全性和耐受性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1260090.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MLYS","BK4139","LENZ"],"gpt_icon":0},{"id":"2518785132","title":"Mineralys Therapeutics, Inc.盘中异动 快速拉升34.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518785132","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518785132?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:31","pubTimestamp":1741613494,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时31分,Mineralys Therapeutics, Inc.股票出现波动,股价大幅拉升34.03%。Mineralys Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.59%。其相关个股中,Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Scisparc Ltd.涨幅较大,Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃,换手率分别为1825.42%、384.06%、45.95%,振幅较大的相关个股有Xencor, Inc.、Seer, Inc.、Y-Mabs Therapeutics, Inc.,振幅分别为99.13%、98.72%、94.67%。Mineralys Therapeutics, Inc.公司简介:Mineralys Therapeutics Inc是一家临床阶段的生物制药公司,专注于开发针对由异常升高的醛固酮引起的疾病的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213134a26a2478&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213134a26a2478&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","MLYS","BK4139"],"gpt_icon":0},{"id":"2517162530","title":"Mineralys Therapeutics, Inc.盘中异动 早盘股价大涨5.19%报10.53美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517162530","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517162530?lang=zh_cn&edition=full","pubTime":"2025-03-06 23:52","pubTimestamp":1741276353,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日23时52分,Mineralys Therapeutics, Inc.股票出现异动,股价快速拉升5.19%。Mineralys Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.55%。Mineralys Therapeutics, Inc.公司简介:Mineralys Therapeutics Inc是一家临床阶段的生物制药公司,专注于开发针对由异常升高的醛固酮引起的疾病的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306235234989ec420&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306235234989ec420&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","MLYS","BK4139"],"gpt_icon":0},{"id":"2514384045","title":"Mineralys Therapeutics, Inc.盘中异动 早盘快速拉升5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514384045","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514384045?lang=zh_cn&edition=full","pubTime":"2025-02-27 23:54","pubTimestamp":1740671642,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日23时54分,Mineralys Therapeutics, Inc.股票出现波动,股价急速上涨5.06%。Mineralys Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.74%。其相关个股中,Quoin Pharmaceuticals Ltd、Alpha Tau Medical Ltd C/Wts 、Heron Therapeutics, Inc.涨幅较大,Quoin Pharmaceuticals Ltd、Aeon Biopharma, Inc.、Moleculin Biotech, Inc.较为活跃,换手率分别为1427.40%、228.24%、108.52%,振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Quoin Pharmaceuticals Ltd、Pds Biotechnology Corporation,振幅分别为86.14%、47.79%、45.45%。Mineralys Therapeutics, Inc.公司简介:Mineralys Therapeutics Inc是一家临床阶段的生物制药公司,专注于开发针对由异常升高的醛固酮引起的疾病的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227235403abdf8352&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227235403abdf8352&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MLYS","LENZ","BK4139"],"gpt_icon":0},{"id":"2514025851","title":"Mineralys Therapeutics, Inc.盘中异动 早盘急速拉升5.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514025851","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514025851?lang=zh_cn&edition=full","pubTime":"2025-02-26 23:02","pubTimestamp":1740582129,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日23时02分,Mineralys Therapeutics, Inc.股票出现波动,股价大幅上涨5.25%。Mineralys Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.24%。其相关个股中,Enveric Biosciences, Inc.、Renovaro Inc.、Humacyte Inc C/Wts 27/08/2026 涨幅较大,Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Aeon Biopharma, Inc.较为活跃,换手率分别为4630.96%、159.46%、142.50%,振幅较大的相关个股有Enveric Biosciences, Inc.、Humacyte Inc C/Wts 27/08/2026 、Renovaro Inc.,振幅分别为155.93%、39.47%、29.31%。Mineralys Therapeutics, Inc.公司简介:Mineralys Therapeutics Inc是一家临床阶段的生物制药公司,专注于开发针对由异常升高的醛固酮引起的疾病的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226230209a254fe07&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226230209a254fe07&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","MLYS","BK4139"],"gpt_icon":0},{"id":"2512601431","title":"Mineralys Therapeutics, Inc.盘中异动 股价大跌5.27%报9.70美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512601431","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512601431?lang=zh_cn&edition=full","pubTime":"2025-02-19 01:09","pubTimestamp":1739898549,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日01时09分,Mineralys Therapeutics, Inc.股票出现异动,股价急速下挫5.27%。Mineralys Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.59%。其相关个股中,Ocean Biomedical Inc C/Wts 14/02/2028 、Solid Biosciences Inc.、Allogene Therapeutics, Inc.涨幅较大,Aditxt, Inc.、Moleculin Biotech, Inc.、Solid Biosciences Inc.较为活跃,换手率分别为496.41%、184.76%、155.32%,振幅较大的相关个股有Estrella Immunopharma Inc C/Wts 29/09/2028、Abvc Biopharma, Inc.、Allogene Therapeutics, Inc.,振幅分别为148.75%、92.00%、79.17%。Mineralys Therapeutics, Inc.公司简介:Mineralys Therapeutics Inc 是一家临床阶段的生物制药公司,专注于开发药物以治疗醛固酮异常升高引起的疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219010910abd3d042&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219010910abd3d042&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","MLYS"],"gpt_icon":0},{"id":"2511667025","title":"Mineralys Therapeutics, Inc.2024财年实现净利润-1.78亿美元,同比减少147.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511667025","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511667025?lang=zh_cn&edition=full","pubTime":"2025-02-16 00:01","pubTimestamp":1739635282,"startTime":"0","endTime":"0","summary":"2月16日,Mineralys Therapeutics, Inc.公布财报,公告显示公司2024财年净利润为-1.78亿美元,同比减少147.57%;其中营业收入为0.00美元,每股基本收益为-3.66美元。机构评级:截至2025年2月16日,当前有7家机构对Mineralys Therapeutics, Inc.目标价做出预测,其中目标均价为32.00美元,其中最低目标价为24.00美元,最高目标价为45.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250216000144a24729ea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250216000144a24729ea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","MLYS"],"gpt_icon":0},{"id":"2511506573","title":"高盛:维持Mineralys Therapeutics(MLYS.US)评级,由买入调整至买入评级, 目标价由28.00美元调整至24.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2511506573","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511506573?lang=zh_cn&edition=full","pubTime":"2025-02-14 01:38","pubTimestamp":1739468289,"startTime":"0","endTime":"0","summary":"高盛:维持Mineralys Therapeutics(MLYS.US)评级,由买入调整至买入评级, 目标价由28.00美元调整至24.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/14013848150609.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","MLYS"],"gpt_icon":0},{"id":"1152728977","title":"Mineralys Therapeutics 第四季度每股收益(0.98)美元,超出(1.04)美元预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1152728977","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152728977?lang=zh_cn&edition=full","pubTime":"2025-02-12 20:06","pubTimestamp":1739361974,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics 报告的季度每股亏损为美元,这比分析师普遍预期的美元高出5.77%。与去年同期每股亏损美元相比,这下降了60.66%。以上内容来自Benzinga Earnings专栏,原文如下:Mineralys $Therapeutics$ reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 5.77 percent. This is a 60.66 percent decrease over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","LENZ"],"gpt_icon":0},{"id":"2510838030","title":"Mineralys Therapeutics, Inc.盘中异动 早盘股价大跌5.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510838030","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510838030?lang=zh_cn&edition=full","pubTime":"2025-02-11 22:39","pubTimestamp":1739284779,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日22时39分,Mineralys Therapeutics, Inc.股票出现波动,股价快速跳水5.21%。Mineralys Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为1.10%。其相关个股中,Dominari Holdings Inc.、Ocean Biomedical, Inc.、Ocean Biomedical Inc C/Wts 14/02/2028 涨幅较大,Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.较为活跃,换手率分别为2226.93%、576.91%、224.48%,振幅较大的相关个股有Ocean Biomedical, Inc.、In8Bio, Inc.、Dominari Holdings Inc.,振幅分别为32.43%、31.80%、29.38%。Mineralys Therapeutics, Inc.公司简介:Mineralys Therapeutics Inc 是一家临床阶段的生物制药公司,专注于开发药物以治疗醛固酮异常升高引起的疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112239409881be96&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112239409881be96&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MLYS","BK4139","LENZ"],"gpt_icon":0},{"id":"2509255744","title":"Mineralys Therapeutics, Inc.盘中异动 早盘股价大涨5.01%报10.55美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509255744","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509255744?lang=zh_cn&edition=full","pubTime":"2025-02-07 22:37","pubTimestamp":1738939056,"startTime":"0","endTime":"0","summary":"北京时间2025年02月07日22时37分,Mineralys Therapeutics, Inc.股票出现波动,股价急速拉升5.01%。截至发稿,该股报10.55美元/股,成交量2926股,换手率0.01%,振幅4.18%。Mineralys Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.02%。Mineralys Therapeutics, Inc.公司简介:Mineralys Therapeutics Inc 是一家临床阶段的生物制药公司,专注于开发药物以治疗醛固酮异常升高引起的疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207223736abc62c1c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207223736abc62c1c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MLYS","LENZ","BK4139"],"gpt_icon":0},{"id":"2509282643","title":"Mineralys Therapeutics, Inc.盘中异动 早盘股价大涨5.39%报10.76美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509282643","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509282643?lang=zh_cn&edition=full","pubTime":"2025-02-05 22:40","pubTimestamp":1738766408,"startTime":"0","endTime":"0","summary":"北京时间2025年02月05日22时40分,Mineralys Therapeutics, Inc.股票出现波动,股价快速上涨5.39%。Mineralys Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为1.64%。其相关个股中,Oragenics Inc.、Pasithea Therapeutics Corp.、Pasithea Therapeutics Corp C/Wts 12/08/2026 涨幅较大,Pasithea Therapeutics Corp.、Oragenics Inc.、60 Degrees Pharmaceuticals, Inc.较为活跃,换手率分别为3280.38%、874.36%、639.41%,振幅较大的相关个股有Estrella Immunopharma Inc C/Wts 29/09/2028、Oragenics Inc.、Pasithea Therapeutics Corp.,振幅分别为54.05%、37.98%、30.29%。Mineralys Therapeutics, Inc.公司简介:Mineralys Therapeutics Inc 是一家临床阶段的生物制药公司,专注于开发药物以治疗醛固酮异常升高引起的疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205224009987b7d5e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205224009987b7d5e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","MLYS","LENZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mineralystx.com","stockEarnings":[{"period":"1week","weight":-0.1071},{"period":"1month","weight":-0.029},{"period":"3month","weight":0.1063},{"period":"6month","weight":1.3883},{"period":"1year","weight":2.1506},{"period":"ytd","weight":2.1275}],"compareEarnings":[{"period":"1week","weight":0.0034},{"period":"1month","weight":0.012},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1445},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.17}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Mineralys Therapeutics, Inc.最初成立于2019年5月31日,是特拉华州的一家公司。该公司是一家临床阶段生物制药公司,专注于开发药物,以治疗由异常升高的醛固酮引起的疾病。该公司的候选产品氯隆前列素是一种专有的口服高选择性醛固酮合酶抑制剂(ASI),该公司最初开发用于治疗未控制的高血压(uHTN)患者,定义为尽管服用了两种或多种抗高血压药物或抵抗性高血压(rHTN),但血压仍不能达到130/80mmHg以下的个体。在美国,有超过1.15亿患者患有持续性高血压(BP)或高血压,超过一半的患者未能实现血压目标,即目前可用的药物血压为130/80 mmHg。超过3000万接受治疗的患者没有达到血压目标,其中约2000万患者的收缩压水平超过140 mmHg。尽管服用了两种或两种以上药物,但高血压患者仍持续存在,心血管疾病或中风导致的死亡率风险分别为1.8倍和2.5倍。在一项评估200名uHTN和rHTN(目标HTN)受试者的第2阶段临床试验中,洛龙前列素显示,每天给药一次,血压下降具有临床意义和统计学意义,且耐受性良好。除高血压外,该公司还打算开发用于治疗慢性肾脏病(CKD)的氯前列素。","exchange":"NASDAQ","name":"Mineralys Therapeutics, Inc.","nameEN":"Mineralys Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mineralys Therapeutics, Inc.(MLYS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Mineralys Therapeutics, Inc.(MLYS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Mineralys Therapeutics, Inc.,MLYS,Mineralys Therapeutics, Inc.股票,Mineralys Therapeutics, Inc.股票老虎,Mineralys Therapeutics, Inc.股票老虎国际,Mineralys Therapeutics, Inc.行情,Mineralys Therapeutics, Inc.股票行情,Mineralys Therapeutics, Inc.股价,Mineralys Therapeutics, Inc.股市,Mineralys Therapeutics, Inc.股票价格,Mineralys Therapeutics, Inc.股票交易,Mineralys Therapeutics, Inc.股票购买,Mineralys Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mineralys Therapeutics, Inc.(MLYS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Mineralys Therapeutics, Inc.(MLYS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}